Health Condition 1: G998- Other specified disorders of nervous system in diseases classified elsewhere Health Condition 2: B338- Other specified viral diseases
Conditions
Interventions
None listed
Sponsors
NIHRLiverppol University
Eligibility
Inclusion criteria
Inclusion criteria: Methodology: Participants: All neurological patients visiting the neurological emergency with the following inclusion and exclusion criteria will be included into the study: 1. Inclusion criteria: a. Patients of Neurological disorders with previously described symptoms related to COVID-19 infection such as: Young Stroke (cerebrovascular accident), Stroke (cerebrovascular accident) patients with deranged prothrombotic states/elevated D-dimer assays, Acute encephalitis, Seizure of unknown etiology, Guillain barre syndrome, Myositis with elevated CPK, para-infectious neurological disorders in the form of myelitis, ADEM, CNS Demyelinating disorders b. Patients of neurological disorders precipitated or preceded by respiratory symptoms in the last 2-4 weeks c. Patients of neurological symptoms (not fitting the criteria of a/b) but found to have lymphopenia / thrombocytopenia /thrombotic states / elevated D-dimer levels 2. Exclusion criteria: a. Patients of neurological disorders with a known etiology other than COVID-19 b. Not giving consent for the study Patients of neurological disorders with suspected COVID-positivity will be included into the study after fulfilling the inclusion and exclusion criteria. Then, they will undergo following assessment for further characterization of the neurological symptoms and signs.
Exclusion criteria
Exclusion criteria: 2. Exclusion criteria: a. Patients of neurological disorders with a known etiology other than COVID-19 b. Not giving consent for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome will be death. Secondary outcomes of interest will be proportions of patients with each neurological diagnosis in the group with neurological disease; admission to a critical (intensive/high dependency) care unit; time to discharge from hospital; and functional outcome at discharge (or 30 days from admission, if still in hospital) - Timepoint: At initial diagnosis and then at 1 month, 3 months, 6 months and 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Drugs on and during admission, such as anticoagulants and antiplatelets 1.SARS-CoV-2 viral load on upper respiratory tract specimen 2.Gender 3.Ethnicity 4.Comorbidities: diabetes, hypertension, obesity, HIV and other immunosuppression 5.Serum C-reactive protein 6.Blood D-dimer concentration 7.Pre-admission general health state (using Clinical Frailty Scale). Timepoint: At initial diagnosis and then at 1 month, 3 months, 6 months and 12 months | — |
Countries
India
Contacts
Public ContactRavi Vasanthapuram
National Institute of mental health & Neurosciences (NIMHANS), Bangalore 29
Outcome results
None listed